查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1961374

免疫肿瘤学检测市场－全球产业规模、份额、趋势、机会、预测：按适应症、技术、地区和竞争格局划分，2021-2031年

Immuno Oncology Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Technology, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球免疫肿瘤学检测市场预计将从 2025 年的 54.7 亿美元成长到 2031 年的 82.1 亿美元，复合年增长率为 7.01%。

这些检测方法作为专门的分析平台，旨在评估癌细胞与免疫系统之间的相互作用，从而支持免疫疗法的研发和患者分层。该市场的成长主要受全球癌症负担日益加重以及精准医疗发展趋势的推动，而精准医疗需要可靠的生物标记来指导治疗方案的选择。根据美国癌症协会预测，到2024年，美国将新增2,001,140例癌症病例，这项数据凸显了开发先进诊断工具以指导治疗性介入和改善临床疗效的迫切需求。

市场概览
预测期 2027-2031
市场规模：2025年 54.7亿美元
市场规模：2031年 82.1亿美元
复合年增长率：2026-2031年 7.01%
成长最快的细分市场 结肠癌
最大的市场 北美洲

儘管市场成长势头强劲，但检测方法的开发和检验需要大量资金投入，这构成了市场面临的重大障碍。专用试剂和复杂分析平台的高昂成本限制了预算有限的小规模研究机构和医疗机构的取得。这种经济壁垒阻碍了这些关键诊断技术的广泛应用，并可能减缓成本敏感地区的市场扩张速度。

市场驱动因素

对免疫疗法研发投入的增加是推动市场成长的主要动力，製药公司正积极开发抗体药物复合体和双特异性抗体等新型治疗方法。这些投入推动了对用于标靶检验、作用机制研究和临床试验监测的专用免疫肿瘤学检测方法的需求。主要产业参与者优先发展癌症治疗产品线，其研发投入规模之大可见一斑。例如，默克公司在2024年2月发布的2023年第四季及全年财报中披露，全年研发支出达到305亿美元，这反映出该公司策略性地加强了包括癌症治疗产品在内的产品线开发。如此巨额的资本投入确保了对筛检和表征不断扩大的免疫疗法候选药物库的高复杂度检测方法的持续需求。

同时，伴随诊断（CDx）的日益普及正在改变市场格局，因为它在检测结果和治疗决策之间建立了至关重要的联繫。随着精准癌症治疗逐渐成为标准疗法，法规结构也在不断发展，要求新药和诊断测试的联合开发，以确保患者合格并最大限度地提高治疗效果。这一趋势迫使诊断试剂製造商快速创新，将PD-L1和MSI状态等生物标记整合到强大的临床平台中。为了支持这一监管趋势，美国食品药物管理局（FDA）在其2024年3月发布的《2023年肿瘤监管审查》中明确指出，2023年核准了15项新的肿瘤设备伴随诊断适应症。此外，主要市场领导的表现也反映了商业性活力。据罗氏公司称，其诊断部门2023财年的基础业务收入增长了7%，这主要得益于2024年对免疫诊断解决方案的持续需求。

市场挑战

免疫肿瘤学检测的研发和检验需要大量的资金投入，这成为市场扩张的主要障碍。建构这些专业诊断平台需要大量的研发成本，不可避免地导致终端用户支付高昂的费用。因此，预算有限的小规模研究机构、地区医院和医疗机构往往无法负担这些先进的分析工具和必要的专用试剂。这种经济差距限制了检测技术的应用，使其主要局限于资金雄厚的学术机构和大型製药公司，阻碍了检测技术在分散环境中的广泛应用，并减缓了检测总量的成长。

全球医疗保健生态系统面临的财政负担加剧了这项挑战。决策者被迫将成本控制置于昂贵技术应用之上。这种巨大的经济压力限制了可用于诊断技术创新的资金。根据美国癌症研究协会 (AACR) 发布的《2024 年癌症进展报告》，预计 2020 年至 2050 年间，癌症造成的全球累积经济负担将达到 25.2 兆美元。如此沉重的财务负担迫使医疗机构限制资本投资，直接阻碍了成本敏感地区免疫肿瘤检测市场的成长。

市场趋势

人工智慧驱动的检测分析技术的整合，透过提升生物标记解读的准确性和处理能力，从根本上重塑了全球免疫肿瘤学检测市场。这些先进的演算法能够对复杂的组织标记进行自动化定量评估，消除了人工病理诊断中固有的变异性，并有助于对肿瘤微环境进行精确表征。这些数位化工具的加速应用也体现在该领域领先创新者的财务表现。根据2025年2月《韩国生物医学评论》的报导《Lunit透过全球扩张与创新实现创纪录的营收成长》，Lunit公司2024年的营收约为3,720万美元，较去年同期成长116%。这主要归功于该公司人工智慧驱动的诊断套件在全球医疗机构的广泛部署。

同时，基于液态生物检体的免疫肿瘤学检测技术的出现，透过实现对治疗反应的非侵入性时间序列监测，推动了市场扩张。这些检测技术透过检测循环肿瘤DNA，克服了组织样本获取的局限性，为微量残存疾病提供了关键讯息，并帮助临床医生快速调整免疫治疗策略。这种向血液检测的转变，在检测数量激增的推动下，正产生显着的商业性动力。根据Guardant Health于2025年2月发布的“2024财年第四季及全年财务业绩”，该公司2024财年总收入达到7.39亿美元，年增31%。这主要归功于临床肿瘤学检测数量增加了20%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球免疫肿瘤学检测市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 适应症（大肠直肠癌、肺癌、恶性黑色素瘤、膀胱癌等）
    • 透过科技（免疫检测、聚合酵素链锁反应（PCR）、次世代定序（NGS）、流式细胞技术）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美免疫肿瘤学检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲免疫肿瘤检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区免疫肿瘤检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲免疫肿瘤检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲免疫肿瘤检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球免疫肿瘤检测市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Agilent Technologies, Inc.
  • BIO-RAD LABORATORIES, INC.
  • Charles River Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • NanoString Technologies, Inc.
  • PerkinElmer Inc.
  • QIAGEN NV
  • Sartorius AG
  • THERMO FISHER SCIENTIFIC, INC.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 24521

The Global Immuno Oncology Assays Market is projected to expand from USD 5.47 Billion in 2025 to USD 8.21 Billion by 2031, registering a compound annual growth rate (CAGR) of 7.01%. These assays serve as specialized analytical platforms designed to assess the interactions between tumor cells and the immune system, thereby aiding in the development of immunotherapies and patient stratification. The market is driven primarily by the increasing global cancer burden and a simultaneous shift toward precision medicine, which demands reliable biomarkers for treatment selection. As reported by the American Cancer Society, it was projected that 2,001,140 new cancer cases would be diagnosed in the United States in 2024, a statistic that underscores the urgent need for advanced diagnostic tools to guide therapeutic interventions and enhance clinical outcomes.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.47 Billion
Market Size 2031USD 8.21 Billion
CAGR 2026-20317.01%
Fastest Growing SegmentColorectal Cancer
Largest MarketNorth America

Despite this positive growth trajectory, the market encounters a significant hurdle regarding the high financial investment necessary for assay development and validation. The substantial costs linked to specialized reagents and complex analytical platforms restrict access for smaller research institutions and healthcare facilities with constrained budgets. This economic barrier impedes the widespread adoption of these essential diagnostic technologies and may decelerate the pace of market expansion in regions that are sensitive to costs.

Market Driver

Increased investment in research and development for immunotherapy acts as a major catalyst for the market, with pharmaceutical companies aggressively pursuing novel therapeutic modalities such as antibody-drug conjugates and bispecific antibodies. This financial dedication fuels the demand for specialized immuno-oncology assays, which are essential for target validation, mechanism-of-action studies, and clinical trial monitoring. The scale of these efforts is evident in the expenditure of major industry players prioritizing oncology pipelines; for instance, Merck & Co., Inc. reported in its 'Fourth-Quarter and Full-Year 2023 Financial Results' in February 2024 that R&D expenses reached $30.5 billion for the full year, reflecting a strategic intensification of their pipeline development, including oncology assets. Such massive capital infusion ensures a continuous need for high-complexity assays to screen and characterize expanding libraries of immunotherapeutic candidates.

Simultaneously, the rising adoption of companion diagnostics (CDx) is transforming the market landscape by establishing a vital link between assay results and therapeutic decision-making. As precision oncology becomes the standard of care, regulatory frameworks are evolving to require the co-development of diagnostic tests with new drugs to ensure patient eligibility and maximize treatment efficacy. This trend compels diagnostic manufacturers to innovate rapidly, integrating biomarkers like PD-L1 and MSI status into robust clinical platforms. Highlighting this regulatory momentum, the U.S. Food and Drug Administration (FDA) noted in its 'Oncology Regulatory Review 2023' in March 2024 that the agency authorized 15 new companion diagnostic indications for oncology devices in 2023. Furthermore, commercial vitality is reflected in the performance of key market leaders; according to Roche, in 2024, the company's Diagnostics Division achieved a 7% growth in base business sales for the 2023 fiscal year, driven largely by sustained demand for immunodiagnostic solutions.

Market Challenge

The substantial financial investment required for the development and validation of immuno-oncology assays presents a significant barrier to market expansion. Creating these specialized diagnostic platforms involves considerable research and development expenditure, which inevitably leads to high pricing for end-users. Consequently, smaller research institutions, community hospitals, and healthcare facilities with limited budgets are often unable to acquire these advanced analytical tools and the necessary specialized reagents. This economic disparity restricts adoption primarily to well-funded academic centers and major pharmaceutical companies, thereby stifling broader market penetration and slowing the overall volume of testing in decentralized settings.

This challenge is further exacerbated by the financial strain on the global healthcare ecosystem, which compels decision-makers to strictly prioritize cost containment over the acquisition of expensive technologies. This intense economic pressure limits the funds available for diagnostic innovation. According to the American Association for Cancer Research (AACR), in its 2024 Cancer Progress Report, the cumulative economic burden of cancer globally is projected to reach $25.2 trillion between 2020 and 2050. Such profound financial liabilities force healthcare providers to limit capital expenditure, directly hampering the growth of the immuno-oncology assays market in cost-sensitive regions.

Market Trends

The integration of AI-enabled assay analytics is fundamentally reshaping the Global Immuno Oncology Assays Market by improving the accuracy and throughput of biomarker interpretation. These advanced algorithms allow for the automated, quantitative scoring of complex tissue markers, addressing the variability inherent in manual pathology and facilitating the precise characterization of the tumor microenvironment. The accelerating adoption of these digital tools is reflected in the financial performance of key innovators in the sector. According to Korea Biomedical Review, February 2025, in the article 'Lunit achieves record revenue growth driven by global expansion, innovation', Lunit reported a 116% year-over-year revenue increase to approximately $37.2 million in 2024, fueled by the expanded deployment of its AI-powered diagnostic suites across global medical institutions.

Concurrently, the emergence of liquid biopsy-based immuno-oncology assays is driving market expansion by enabling non-invasive, longitudinal monitoring of treatment response. These assays overcome the limitations of tissue availability by detecting circulating tumor DNA, providing critical insights into minimal residual disease and helping clinicians rapidly adjust immunotherapeutic strategies. This shift towards blood-based testing is generating significant commercial momentum as test volumes surge. According to Guardant Health, February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company achieved total revenue of $739 million for the fiscal year 2024, marking a 31% increase from the prior year, primarily driven by a 20% growth in clinical oncology test volume.

Key Market Players

  • Agilent Technologies, Inc.
  • BIO-RAD LABORATORIES, INC.
  • Charles River Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • NanoString Technologies, Inc.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Sartorius AG
  • THERMO FISHER SCIENTIFIC, INC.

Report Scope

In this report, the Global Immuno Oncology Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immuno Oncology Assays Market, By Indication

  • Colorectal Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Bladder Cancer
  • Others

Immuno Oncology Assays Market, By Technology

  • Immunoassays
  • Polymerase chain reaction (PCR)
  • Next-generation sequencing (NGS)
  • Flow Cytometry

Immuno Oncology Assays Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immuno Oncology Assays Market.

Available Customizations:

Global Immuno Oncology Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immuno Oncology Assays Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Colorectal Cancer, Lung Cancer, Melanoma Cancer, Bladder Cancer, Others)
    • 5.2.2. By Technology (Immunoassays, Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Flow Cytometry)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Immuno Oncology Assays Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Immuno Oncology Assays Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Immuno Oncology Assays Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Immuno Oncology Assays Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Technology

7. Europe Immuno Oncology Assays Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Technology
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Immuno Oncology Assays Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Technology
    • 7.3.2. France Immuno Oncology Assays Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Technology
    • 7.3.3. United Kingdom Immuno Oncology Assays Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Technology
    • 7.3.4. Italy Immuno Oncology Assays Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Immuno Oncology Assays Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Technology

8. Asia Pacific Immuno Oncology Assays Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Technology
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Immuno Oncology Assays Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Immuno Oncology Assays Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Immuno Oncology Assays Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Immuno Oncology Assays Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Immuno Oncology Assays Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Technology

9. Middle East & Africa Immuno Oncology Assays Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Technology
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Immuno Oncology Assays Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Technology
    • 9.3.2. UAE Immuno Oncology Assays Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Technology
    • 9.3.3. South Africa Immuno Oncology Assays Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Technology

10. South America Immuno Oncology Assays Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Technology
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Immuno Oncology Assays Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Technology
    • 10.3.2. Colombia Immuno Oncology Assays Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Technology
    • 10.3.3. Argentina Immuno Oncology Assays Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Immuno Oncology Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. BIO-RAD LABORATORIES, INC.
  • 15.3. Charles River Laboratories, Inc.
  • 15.4. F. Hoffmann-La Roche Ltd
  • 15.5. Illumina, Inc.
  • 15.6. NanoString Technologies, Inc.
  • 15.7. PerkinElmer Inc.
  • 15.8. QIAGEN N.V.
  • 15.9. Sartorius AG
  • 15.10. THERMO FISHER SCIENTIFIC, INC.

16. Strategic Recommendations

17. About Us & Disclaimer